Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
IM-96 by Beijing Immunochina Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval
IM-96 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to...